Study of cadisegliatin added to insulin for type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests an investigational pill (called cadisegliatin) added to your usual insulin treatment for people with type 1 diabetes who use an automated insulin pump. It aims to improve blood sugar control and reduce the time your sugar is too high.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have type 1 diabetes, not type 2 or other rare forms.
- Your blood sugar control (measured by time in range) must be under 70% — meaning your glucose is not in the target range often enough.
- You must be using a hybrid closed loop insulin pump for at least 3 months and be willing to keep using the same pump model during the study.
- You must be willing to wear a study-provided continuous glucose monitor (CGM) throughout the study.
- You must have normal liver function (checked by blood tests) and not have had diabetic ketoacidosis in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.
This study tests whether adding a weekly injection of tirzepatide (a drug that helps with blood sugar and weight) can improve glucose control in adults with type 1 diabetes who already use an automated insulin pump. It may help you if your blood sugar is not at target despite using a pump.
This trial tests a drug that may help your body use insulin better and improve how your cells produce energy. It might lead to better blood sugar control and less insulin needed.
This study tests a smart insulin pump and continuous glucose monitor system that adjusts insulin automatically and uses behavior support to improve blood sugar control. It's for people with type 1 diabetes who have used an approved automated insulin delivery system recently and are willing to use study devices.
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.